Publication: Monoklonal antikor içeren manyetik nanopartiküllerin hazırlanması ve in vitro özelliklerinin incelenmesi
Abstract
ÖZETAmaç: Kontrollü ilaç salım sistemleri, ilacın istenen konsantrasyon aralığında kalmasını sağlayarak dozlama aralığını arttırılmasını, istenen bölgeye hedaflendirilerek ilacın diğer dokulara olabilecek hasarın ortadan kaldırılmasını sağlamaktadır. Özellikle ilacın gözün arka kısmı gibi ulaşılması zor bölgelere iletilmesinde, birçok yan etkisi bulunan intravitreal enjeksiyon yerine kullanılması avantaj sağlayacaktır. Bu nedenle çalışmada, oküler hastalıkların tedavisinde kullanılabilirliğinin araştırılması için “Ranibizumab” antikorunun konjuge edildiği, altın kaplı manyetit nanopartiküllerin hazırlanması ve karakterize edilmesi amaçlanmıştır.Gereç ve Yöntem: Altın kaplı manyetit nanopartiküller hazırlanarak üzerine Ranibizumab antikoru konjuge edilmiştir. Elde edilen bu sistem Taramalı Elektron Mikroskobu (SEM), Termogravimetrik Analiz (TGA), Dinamik Işık Saçılması (DLS), X-Işını Kırınımı (XRD) yöntemleri kullanılarak karakterize edilmiş ve MTT testi ile toksisitesi değerlendirilmiştir.Bulgular: Yapılan karakterizasyon çalışmaları ile; hazırlanan altın kaplı manyetit nanopartiküllerin dışarıdan uygulanan manyetik alan ile yönlendirilebildiği, yaklaşık 160 nm boyutlarında, -21,1 mV yüzey yüküne sahip olduğu ve antikor konjugasyonuna bağlı olarak boyutun arttığı, yaklaşık %50 verimle konjuge edilen antikorun %60' ının ilk yarım saatte salındığı, salım sonrası antikorların biyolojik aktivitesini koruduğu ve nanopartiküllerin toksik olmadığı gösterilmiştir.Sonuçlar: Çalışmamızda Ranibizumab konjuge edilen altın kaplı manyetit nanopartiküllerin başarı ile hazırlandığı, hedeflenebilme özelliğine de sahip olan bu nanopartiküllerin kontrollü salım sistemi olarak oküler hastalıkların tedavisinde kullanılabilir olduğu gösterilmiştir.
ABSTRACTAim: Controlled drug delivery systems ensure that increasing the dosing interval by allowing the drug concentration to remain in the desired range and eliminating the damage to other tissues of the drug by targeted the desired area. In particular, the delivery of the drug to difficult-to-reach areas, such as the back of the eye, would be advantageous when used instead of intravitreal injection wich have many side effects. Therefore, in this study, it was aimed to prepare and characterize to Ranibizumab conjugated gold-coated magnetite nanoparticles for investigate the usability on ocular diseases.Materials and Methods: Gold-coated magnetite nanoparticles were prepared and Ranibizumab conjugated onto this particles. This system was characterized by using Scanning Electron Microscope (SEM), Thermogravimetric Analysis (TGA), Dynamic Light Scattering (DLS), X-Ray Diffraction (XRD) methods and the toxicity of nanoparticles was evaluated by MTT assay.Results: It was shown that prepared gold coated magnetite nanoparticles can be directed by externally applied magnetic field, they have approximately 160 nm in size and have a surface charge of-21,1 mV, increase in size due to antibody conjugation, about 60% of the conjugated antibody is released in the first half hour. Also it was shown that the antibodies retained their biological activity after release and the nanoparticles were not toxic.Conclusions: In this study, it has been shown that the Ranibizumab conjugated gold coated magnetite nanoparticles, which have the ability to be targeted, were prepared successfully and can be used in the treatment of ocular diseases as a drug delivery system.
ABSTRACTAim: Controlled drug delivery systems ensure that increasing the dosing interval by allowing the drug concentration to remain in the desired range and eliminating the damage to other tissues of the drug by targeted the desired area. In particular, the delivery of the drug to difficult-to-reach areas, such as the back of the eye, would be advantageous when used instead of intravitreal injection wich have many side effects. Therefore, in this study, it was aimed to prepare and characterize to Ranibizumab conjugated gold-coated magnetite nanoparticles for investigate the usability on ocular diseases.Materials and Methods: Gold-coated magnetite nanoparticles were prepared and Ranibizumab conjugated onto this particles. This system was characterized by using Scanning Electron Microscope (SEM), Thermogravimetric Analysis (TGA), Dynamic Light Scattering (DLS), X-Ray Diffraction (XRD) methods and the toxicity of nanoparticles was evaluated by MTT assay.Results: It was shown that prepared gold coated magnetite nanoparticles can be directed by externally applied magnetic field, they have approximately 160 nm in size and have a surface charge of-21,1 mV, increase in size due to antibody conjugation, about 60% of the conjugated antibody is released in the first half hour. Also it was shown that the antibodies retained their biological activity after release and the nanoparticles were not toxic.Conclusions: In this study, it has been shown that the Ranibizumab conjugated gold coated magnetite nanoparticles, which have the ability to be targeted, were prepared successfully and can be used in the treatment of ocular diseases as a drug delivery system.